Skip to main content

Table 3 Comparison of angiogenesis cytokines among RS3PE with/without malignancy, OA, and EORA

From: bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients

  RS3PE with malignancy (n = 8) RS3PE without malignancy (n = 38) OA (n = 15) EORA (n = 14) F/t P
Flt-1 (ng/mL) 7.38±2.64 6.14±2.25 5.96±1.53 5.59±1.67 1.321 0.275
PlGF (ng/mL) 6.14 (4.436, 6.58) 5.99 (4.45, 7.29) 5.61(4.74, 6.6) 4.81 (4.48, 7.15) 0.745 0.863
Tie-2 (ng/mL) 8.99±2.34 9.92±2.89 11.26±2.72 8.47±2.41 2.816 0.045
VEGF (ng/mL) 168.41 (90.86, 327.61) 83.15 (50.34, 200.11) 156.24 (117.94, 239.03) 71.68 (40.74, 234.95) 4.144 0.246
VEGF-C (ng/mL) 3.76 (1.69, 7.58) 4.75 (3.72, 9.79) 6.57 (5.45, 7.82) 5.31 (3.87, 6.46) 3.281 0.350
VEGF-D (ng/mL) 18.40 (14.86, 30.31) 31.92 (26.88, 46.75) 26.43 (23.64, 36.74) 24.98 (17.56, 34.74) 10.433 0.015
bFGF (ng/mL) 14.21 (7.52, 23.18) 4.32 (2.88, 7.42) 3.23 (1.96, 5.59) 3.20 (2.20, 5.30) 15.861 0.001
MMP-3 (ng/mL) 24.74 (17.96, 51.67) 36.08 (19.01, 54.34) 22.03 (14.84, 25.57) 33.31 (15.86, 41.44) 5.346 0.148
MMP-1 (ng/mL) 4.98 (3.80, 7.50) 3.93 (1.94, 7.73) 2.90 (1.72, 4.50) 5.80 (3.37, 10.73) 5.472 0.140
MMP-7 (ng/mL) 2.11 (1.55, 5.02) 2.86 (1.99, 3.40) 2.68 (1.64, 4.16) 3.06 (2.02, 5.03) 0.864 0.834
TRAIL (pg/mL) 82.28 (57.26, 121.38) 93.86 (75.98, 140.34) 98.56 (84.51, 114.28) 89.96 (61.04, 124.94) 2.324 0.508
Mesothelin (ng/mL) 25.65 (17.81, 34.84) 24.10 (17.89, 30.54) 27.20 (15.40, 30.27) 21.96 (18.94, 28.50) 0.688 0.876
  1. Note: Significance comparing with RS3PEpatients with malignancy, adjusted P<0.05. RS3PE remitting seronegative symmetrical synovitis with pitting edema, Flt-1 Fms-like tyrosine kinase 1, VEGF vascular endothelial growth factor, PIGF placental growth factor, bFGF basic fibroblast growth factor, MMP matrix metalloproteinase, TRAIL tumor necrosis factor-related apoptosis-inducing ligand